文献速递甲状腺核医学肿瘤 PET/CT

[18F]DOPA PET/ceCT 在甲状腺髓样癌术前诊断与分期中的应用

[18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-05-15

研究纳入32例超声可疑甲状腺结节且降钙素病理升高患者,术前行[18F]DOPA PET/ceCT,以术后组织学为参考评估原发灶及淋巴结分期。DOPA PET/ceCT诊断原发甲状腺髓样癌灵敏度88%,中央区和侧区淋巴结转移灵敏度分别为53%和73%,均优于颈部超声的20%和39%。多因素分析显示仅DOPA PET/ceCT cN1b状态预测术后肿瘤持续存在(P=0.016,相对危险度4.02)。

要点

  • DOPA PET/ceCT诊断原发甲状腺髓样癌灵敏度88%,未检出者均为pT1a。
  • 中央区和侧区淋巴结转移灵敏度分别为53%和73%,高于超声的20%和39%。
  • DOPA PET/ceCT cN1b状态独立预测术后肿瘤持续存在(P=0.016,相对危险度4.02)。

核心结论

  • DOPA PET/ceCT诊断原发甲状腺髓样癌灵敏度高,检测淋巴结转移灵敏度优于超声。
  • DOPA PET/ceCT识别的N1b状态预测术后肿瘤持续存在。
  • 作者认为实施DOPA引导的淋巴结清扫可能改善手术成功率。

研究设计与样本

  • 研究纳入32例超声可疑甲状腺结节且基础及刺激后降钙素病理升高的患者,术前行DOPA PET/ceCT。
  • 以术后组织学作为超声和DOPA PET/ceCT区域淋巴结分期的参考标准。
  • 采用单因素和多因素回归分析及受试者工作特征分析评估术前与组织学参数和术后肿瘤持续或复发的关系。

主要发现

  • 全部32例组织学证实为原发甲状腺髓样癌,其中28例原发肿瘤DOPA脱羧酶活性增高(灵敏度88%,平均SUVmax 10.5)。
  • 未检出肿瘤者均为pT1a期。
  • DOPA PET检测中央区和侧区转移性颈部淋巴结的灵敏度分别为53%和73%,颈部超声分别为20%和39%。
  • 单因素回归分析中,术前基础降钙素和癌胚抗原水平、cN1b状态及DOPA PET/ceCT显示受累颈部区域数与术后肿瘤持续/复发相关(P<0.05)。
  • 多因素分析中仅DOPA PET/ceCT cN1b状态保持显著(P=0.016,相对危险度4.02)。

临床怎么用

  • 作者认为,DOPA引导的淋巴结清扫可能改善手术成功率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Medullary thyroid carcinoma (MTC) is characterized by a high rate of metastasis. In this study we evaluated the ability of [18F]DOPA PET/ceCT to stage MTC in patients with suspicious thyroid nodules and pathologically elevated serum calcitonin (Ctn) levels prior to total thyroidectomy and lymph node (LN) dissection. METHODS: A group of 32 patients with sonographically suspicious thyroid nodules and pathologically elevated basal Ctn (bCtn) and stimulated Ctn (sCtn) levels underwent DOPA PET/ceCT prior to surgery. Postoperative histology served as the standard of reference for ultrasonography and DOPA PET/ceCT region-based LN staging. Univariate and multivariate regression analyses as well as receiver operating characteristic analysis were used to evaluate the correlations between preoperative and histological parameters and postoperative tumour persistence or relapse. RESULTS: Primary MTC was histologically verified in all patients. Of the 32 patients, 28 showed increased DOPA decarboxylase activity in the primary tumour (sensitivity 88%, mean SUVmax 10.5). Undetected tumours were exclusively staged pT1a. The sensitivities of DOPA PET in the detection of central and lateral metastatic neck LN were 53% and 73%, in contrast to 20% and 39%, respectively, for neck ultrasonography. Preoperative bCtn and carcinoembryonic antigen levels as well as cN1b status and the number of involved neck regions on DOPA PET/ceCT were predictive of postoperative tumour persistence/relapse in the univariate regression analysis (P < 0.05). Only DOPA PET/ceCT cN1b status remained significant in the multivariate analysis (P = 0.016, relative risk 4.02). CONCLUSION: This study revealed that DOPA PET/ceCT has high sensitivity in the detection of primary MTC and superior sensitivity in the detection of LN metastases compared to ultrasonography. DOPA PET/ceCT identification of N1b status predicts postoperative tumour persistence. Thus, implementation of a DOPA-guided LN dissection might improve surgical success.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rasul S, Hartenbach S, Rebhan K, et al. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur J Nucl Med Mol Imaging. 2018. PMID: 29766245. doi:10.1007/s00259-018-4045-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。